Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

e risk that the sale of the company's pulmonary business assets to Novartis Pharmaceuticals Corporation may not close or the closing may be delayed, (v) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 650-631-4954

jruddock@nektar.com

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share information)

Unaudited Unaudited

Three-Months Ended Nine-Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue:

Product sales and royalties $9,474 $37,497 $28,855 $159,818

Contract research 11,965 18,824 32,977 47,436

Total revenue 21,439 56,321 61,832 207,254

Ope
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 ZAMST, a leader ... endorsement deal with professional baseball star Nolan Arenado ... best young baseball players, Arenado will be working with ... specific product category. , Arenado was selected by ... #59 overall. In 2013, Arenado was awarded the Gold ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring ... on his role as a kicking coach, his kicking business, ... according to retired NFL kicker Michael Husted author of HustedKicking.com. ... and is one of the top pro free agent kickers ... with Anthony at our 2014 Pro Camp and I was ...
(Date:9/2/2014)... 2014: Health structures explain nearly 20% of the ... results of a joint ESC-OECD study presented today ... variables explained more than 80% of non-adherence. , ... which combines clinical data and health structure characteristics ... of the reasons some patients with heart failure ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 NOVAtime ... Management solution development company, announced today that Avon ... 2009, has upgraded to NOVAtime 4000 Time ... conjunction with NOVAtime’s latest smart clock, the ... Farmington Valley of Connecticut is an award-winning nursing ...
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... for women are long gone. But even though men shave ... an unhealthy appearance – rough and irritated skin isn’t inevitable, ... Advanced Dermatology P.C. , For decades, skin care ... years have witnessed a surge in men of all ages ...
Breaking Medicine News(10 mins):Health News:Gold Glove Baseball Star Nolan Arenado Signs With Zamst 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3
... -- There are major differences between oncologists and primary ... care for American,s 12 million cancer survivors. That ... survey of doctors that reveals how these differences pose ... following initial cancer treatment. The study, published online ...
... When looking at a picture of many trees, young people ... we get, the more likely we are to notice a single ... which the brain processes the bigger picture is slower in older ... Elseviers Cortex , researchers have found that these age-related changes ...
... , SUNDAY, July 24 (HealthDay News) -- Young children ... so parents should be especially vigilant monitoring their kids around ... Centre of The Montreal Children,s Hospital also warned that toddlers ... to recognize potential dangers at a pool. Mandatory fencing ...
... By Steven Reinberg HealthDay Reporter , SUNDAY, July ... a new anti-clotting drug, Eliquis, to dual antiplatelet therapy may ... attack and stroke, a new study finds. A trial ... of severe bleeding among those taking Eliquis (apixaban) became apparent. ...
... HealthDay Reporter , FRIDAY, July 22 (HealthDay News) ... difficulty understanding medical information, your health may be at risk. ... that low health literacy is linked with many types of ... "There are no real surprises here," said study author Nancy ...
... News) -- Eager young athletes will be taking to sports ... to be protected from heat exhaustion and heat stroke, a ... safe is "hydration, hydration, hydration," Dr. Toni Salvatore, medical director ... in a hospital news release. Drinking adequate amounts of ...
Cached Medicine News:Health News:Study: Doctors differ in how best to care for America's 12 million cancer survivors 2Health News:Study: Doctors differ in how best to care for America's 12 million cancer survivors 3Health News:Older people find it harder to see the wood for the trees 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3Health News:Low 'Health Literacy' Hazardous to Your Health 2
(Date:9/2/2014)... SAN ANTONIO , Sept. 2, 2014 /PRNewswire/ ... private medical technology company focused on innovating lifesaving ... announced the appointment of Dr. Gabriele Niederauer ... President and CEO. Following the recent closure of ... CE Mark for the Surfacer™ Inside-Out Access Catheter ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
(Date:9/2/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... its lipid franchise were highlighted in four presentations at ... Barcelona Spain . Isis has created ... effective and safe therapeutic options to treat patients with ... drug and several other drugs in clinical development designed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5
... , the leading online Medical Transcription and Editing training ... NexGen Speech Recognition Editing and Medical Transcription Program. In ... MTEC is moving their curriculum to the next level. ... this important industry migration and is being provided to ...
... Medical Messenger , an innovative healthcare technology ... 4 is now certified to meet 2011-2012 criteria supporting ... and Reinvestment Act (ARRA) as a Complete EHR by ... record (EHR) software capable of enabling providers to meet ...
Cached Medicine Technology:MTEC Announces Release of NexGen Speech Recognition Editing and Medical Transcription Training Program 2Medical Messenger's AstralJet V4 Receives ONC-ATCB 2011/2012 Certification 2
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
Medicine Products: